VTGN Archives - BioTuesdays

Developments

FDA fast tracks Vistagen’s PH10 for major depressive disorder

The FDA granted Vistagen (NASDAQ:VTGN) fast track designation for development of PH10, an investigational nasal sprays, for the treatment of major depressive disorder (MDD). The FDA decision aligns with “our belief in...

December 6, 2022

Developments

Vistagen continuing second Phase 3 trial in social anxiety disorder

Vistagen Therapeutics (NASDAQ:VTGN) announced completion of an interim analysis of PALISADE-2, its second Phase 3 clinical trial assessing drug candidate, PH94B, as an acute treatment of anxiety in adults with social...

September 8, 2022

Developments

VistaGen fails Phase 3 trial in social anxiety disorder

VistaGen Therapeutics’ (NASDAQ:VTGN) topline results from its PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder did not achieve its primary endpoint, as...

July 22, 2022

Developments

VistaGen expands PH948 in Phase 2a trial for adjustment disorder

VistaGen Therapeutics (NASDAQ:VTGN) initiated a Phase 2a clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety...

October 14, 2021

Developments

VistaGen reports new mechanism of action data for PH94B

VistaGen Therapeutics (NASDAQ:VTGN) announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats demonstrating that a single intranasal administration of radiolabeled carbon-14...

October 5, 2021

Feature

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

VistaGen Therapeutics (NASDAQ:VTGN) plans to begin a Phase 3 clinical trial in the second quarter with PH94B, a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in...

February 9, 2021

Markets

WB ups VistaGen Therapeutics to OP; fair value estimate $9

William Blair upgraded VistaGen Therapeutics (NASDAQ:VTGN) to “outperform” with a fair value estimate of $9, citing a “clearly skewed risk/reward” for the shares. The stock closed at $1.94 on Dec. 31. VistaGen is...

January 4, 2021

Developments

VistaGen reports positive results from Phase 2a major depressive disorder study

VistaGen Therapeutics (NASDAQ:VTGN) reported positive results from its Phase 2a clinical study of PH10 for treatment of major depressive disorder (MDD). PH10 is a synthetic neurosteroid nasal spray designed to activate...

February 20, 2020

Developments

FDA clears VistaGen’s IND for Phase 2 levodopa-induced dyskinesia study

The FDA cleared VistaGen Therapeutics’ (NASDAQ:VTGN) IND for AV-101 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, enabling the company to proceed with Phase 2...

January 30, 2020

Markets

WB cuts VistaGen to MP; Maxim maintains buy but cuts PT to $1 from $4

William Blair downgraded VistaGen Therapeutics (NASDAQ:VTGN) to “market perform” after the Phase 2 ELEVATE study of AV-101 for the adjunctive treatment of major depressive disorder (MDD) failed to meet its primary...

November 14, 2019

Tag - VTGN

FDA fast tracks Vistagen’s PH10 for major depressive disorder

Vistagen continuing second Phase 3 trial in social anxiety disorder

VistaGen fails Phase 3 trial in social anxiety disorder

VistaGen expands PH948 in Phase 2a trial for adjustment disorder

VistaGen reports new mechanism of action data for PH94B

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

WB ups VistaGen Therapeutics to OP; fair value estimate $9

VistaGen reports positive results from Phase 2a major depressive disorder study

FDA clears VistaGen’s IND for Phase 2 levodopa-induced dyskinesia study

WB cuts VistaGen to MP; Maxim maintains buy but cuts PT to $1 from $4

General

More